Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 34,980 Shares of Stock
BridgeBio Pharma CEO Neil Kumar sold 34,980 shares of the company's stock for approximately $2.89 million, reducing his holdings by 12.57%. This sale occurred as BridgeBio reported a quarterly loss that missed analyst estimates, although revenue saw a significant year-over-year increase. Despite the insider selling and a slight stock decline, analysts maintain a "Moderate Buy" rating with an average price target of $100.79.
Neil Kumar Sells 10,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock
BridgeBio Pharma CEO Neil Kumar recently sold 10,000 shares of the company's stock for $840,300, reducing his ownership by 1.94%. This transaction, along with previous sales, was made under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling and a recent earnings miss, analysts generally maintain a "Moderate Buy" rating for BBIO with a consensus price target of $100.79.
Bridgebio Pharma Insider Sold Shares Worth $3,727,251, According to a Recent SEC Filing
An insider at Bridgebio Pharma (BBIO) recently sold shares valued at $3,727,251, according to a recent SEC filing. The company, a biopharmaceutical firm focused on genetic diseases, had its shares trading at $82.94 USD with a slight daily decrease but significant year-to-date growth. This transaction follows other recent news regarding the company's secondary offering and Q2 2026 earnings report.
Family trust tied to BridgeBio (NASDAQ: BBIO) plans new stock sale
A family trust associated with BridgeBio Pharma, Inc. (BBIO), the Kumar Haldea Family Irrevocable Trust, intends to sell 30,000 shares of common stock valued at approximately $2.49 million. This sale, detailed in a Form 144 SEC filing, follows previous 10b5-1 sales by Neil Kumar and related trusts. The shares originated from a "Conversion Management Incentive Units" acquisition in 2016.
Will BridgeBio’s (BBIO) US$390 Million Raise and Late‑Stage Pipeline Progress Change Its Narrative?
BridgeBio Pharma, Inc. recently completed a US$390 million equity offering and reported Q2 2026 revenues of US$243.68 million with a net loss of US$152.22 million. The company also highlighted new clinical data for Attruby and advanced its rare-disease pipeline with regulatory progress for BBP-418 and encaleret. This fresh capital and pipeline progress are expected to support its genetic medicines portfolio and potentially reshape BridgeBio’s investment narrative, although ongoing net losses and future capital needs remain a key risk.
BridgeBio (NASDAQ: BBIO) CEO has 71K RSUs vest, withholds shares for taxes
BridgeBio Pharma, Inc. CEO Neil Kumar had 71,217 Restricted Stock Units (RSUs) convert into common stock on August 16, 2026. To cover tax obligations from this vesting, 36,237 shares were withheld at $79.86 per share. Following these transactions, Kumar's indirect holdings across various trusts were reported, totaling over 4.8 million shares, while he disclaims beneficial ownership except for any pecuniary interest.
BridgeBio (NASDAQ: BBIO) insider plans $2.8M stock sale
BridgeBio Pharma, Inc. (BBIO) insider Neil Kumar plans to sell 34,980 shares of common stock, valued at approximately $2.8 million, under Rule 144. The filing also details previous Rule 10b5-1 plan sales by Kumar and related trusts over the past three months. This sale represents a small fraction of the 195,487,474 shares outstanding as of August 18, 2026.
Form 8K BridgeBio Pharma Inc For: 17 August By Investing.com
This article announces that BridgeBio Pharma Inc. has filed a Form 8K for August 17th. The brief piece includes the stock symbol BBIO and its performance, but provides no further details about the content of the 8K filing. It appears to be an automated notification from Investing.com.
BridgeBio Pharma (NASDAQ: BBIO) shareholder schedules August stock sale
A BridgeBio Pharma shareholder plans to sell 21,501 shares of common stock, valued at approximately $1.7 million, on August 17, 2026, through Morgan Stanley Smith Barney LLC. This sale is associated with the exercise of stock options. The filing also notes previous 10b5-1 plan sales by Randal Scott of 2,196 shares in June 2026.
Q4 2025 BridgeBio Pharma Inc Earnings Call Transcript
BridgeBio Pharma Inc. reported strong commercial execution in Q4 2025, driven by significant revenue growth from Attruby and positive Phase 3 results for several pipeline assets. The company is transitioning towards generating significant cash flows by 2028, supported by a robust financial position. Despite these achievements, its share price performance has not fully reflected the progress, primarily due to uncertainties surrounding the tafamidis IP situation and rising operating costs.
BridgeBio Pharma Inc (HAM:2CL) Stock Price & 30 Year Financial Data
This article provides comprehensive 30-year financial data for BridgeBio Pharma Inc (HAM:2CL) from GuruFocus, including growth rates for revenue, EPS, EBIT, EBITDA, and free cash flow. It details the company's market capitalization, enterprise value, and various financial ratios, offering an in-depth financial overview for investors. The content is presented with extensive filtering and export options, emphasizing historical financial performance.
BridgeBio Pharma (BBIO) Secured Two Priority Reviews For Rare Disease Drugs
BridgeBio Pharma (BBIO) has achieved significant clinical and regulatory milestones for its rare disease drugs, acoramidis, BBP-418, and encaleret. BBP-418 and encaleret have both received Priority Review status, with BBP-418 potentially being the first therapy for LGMD2I/R9. These developments signify BridgeBio Pharma's transition towards a commercial-stage model within the rare disease market, supported by strong Q2 2026 revenue figures and a multi-product launch strategy.
Assenagon Asset Management S.A. Has $1.16 Million Holdings in BridgeBio Pharma, Inc. $BBIO
Assenagon Asset Management S.A. reduced its stake in BridgeBio Pharma, Inc. by 64.6% in the second quarter, holding 15,620 shares valued at $1.16 million. Despite this, institutional investors collectively own 99.85% of BBIO, and analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $100.79. The company recently reported strong revenue growth but missed EPS estimates, while insiders have sold a significant number of shares.
Analyst Estimates: Here's What Brokers Think Of BridgeBio Pharma, Inc. (NASDAQ:BBIO) After Its Second-Quarter Report
This article analyzes what brokers think of BridgeBio Pharma, Inc. (NASDAQ:BBIO) following its second-quarter report. It would likely detail analyst ratings, price targets, and any changes in sentiment post-earnings, providing insights into the company's financial performance and future outlook from an investment perspective.
KKR to Sell 5M BridgeBio Shares; Company Receives No Proceeds
BridgeBio Pharma announced the pricing of a secondary offering of 5,000,000 shares of its common stock by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not issue any shares or receive any proceeds from this transaction, which is expected to close on August 17, 2026. Following the news, BBIO's stock declined 1.42%, with high trading volume indicating selling pressure.
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
BridgeBio Pharma, Inc. announced the pricing of an oversubscribed secondary offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P. The company itself is not selling shares and will not receive any proceeds from the offering. This transaction aims to further diversify BridgeBio's institutional shareholder base towards high-quality, long-term ownership.
BridgeBio Pharma (BBIO) holders to resell 5M shares in $390M offering
BridgeBio Pharma is facilitating a secondary offering where a KKR-affiliated selling stockholder will sell 5,000,000 shares of common stock at $78.00 per share, totaling $390 million. BridgeBio Pharma will not receive any proceeds from this transaction, as all net proceeds will go to the selling stockholder. This offering will reduce KKR's stake in BridgeBio from 7.3% to 4.7%, representing a change in ownership rather than new issuance of shares.
KKR reportedly assigned almost 60% of BridgeBio stock sale to five firms
KKR reportedly allocated nearly 60% of its BridgeBio Pharma stock sale to the top five participating investors. This information comes from Bloomberg, citing sources familiar with the matter. BridgeBio Pharma is based in Palo Alto, California.
BridgeBio Pharma Announces Secondary Offering of 5 Million Shares
BridgeBio Pharma has announced a secondary offering of 5 million shares. This news follows a recent report from RBC stating that BridgeBio Pharma's transition to a rare disease "commercial powerhouse" is on track. The company's stock price closed at $79.86 USD on August 14th.
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
BridgeBio Pharma announced the pricing of a secondary offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P., which is expected to diversify its institutional shareholder base. BridgeBio itself is not selling any shares and will not receive any proceeds from this offering. The transaction is anticipated to close on August 17, 2026.
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has announced a secondary public offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P., an existing shareholder. BridgeBio itself is not selling any shares and will not receive any proceeds from this offering. William Blair, Goldman Sachs & Co. LLC, and KKR are acting as joint book-running managers for the proposed offering.
KKR Proposes Sale of 5 Million BridgeBio Pharma Shares in Offering
BridgeBio Pharma (BBIO) announced a secondary public offering of 5,000,000 shares of its common stock, to be sold by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not sell any shares in this transaction and will not receive any proceeds. The offering is subject to market conditions and is being made under an automatic shelf registration statement.
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has announced the launch of a secondary public offering of 5,000,000 shares of its common stock by existing shareholder KKR Genetic Disorder L.P. The company itself is not selling any shares and will not receive any proceeds from the offering. William Blair, Goldman Sachs & Co. LLC, and KKR are serving as joint book-running managers for the proposed offering.
Analysts Have Made A Financial Statement On BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Second-Quarter Report
BridgeBio Pharma Inc. (NASDAQ:BBIO) saw its shares rise 2.3% after its second-quarter report, with revenues of US$244m beating expectations but statutory losses widening to US$0.78 per share. Analysts have updated their forecasts, projecting US$1.01b in revenues for 2026, a 42% increase, while expecting losses per share to narrow to US$2.75. Despite increased loss per share expectations, the consensus price target remained at US$108, indicating that revenue growth is offsetting concerns about rising losses.
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $111.00
JPMorgan Chase & Co. has increased its price target for BridgeBio Pharma (NASDAQ:BBIO) to $111.00 from $100.00, maintaining an "overweight" rating and suggesting a 32.73% potential upside. This comes as the company's Q2 revenue significantly beat estimates, growing 120.4% year-over-year to $243.68 million, despite missing analyst expectations for earnings per share. Several other analysts have also raised their price targets for BBIO, contributing to a "Moderate Buy" consensus rating with an average target of $100.42.
Tema ETFs LLC Trims Stock Position in BridgeBio Pharma, Inc. $BBIO
Tema ETFs LLC significantly reduced its stake in BridgeBio Pharma, Inc. by 32.2% in the second quarter, selling 36,197 shares but still retaining 76,076 shares valued at $5.67 million. Despite institutional investors owning 99.85% of BBIO and a consensus "Moderate Buy" rating with a $99.53 price target, the company reported a wider-than-expected loss per share in Q2, even as revenue exceeded estimates. Recent insider selling by directors further highlights mixed sentiment surrounding the stock.
BridgeBio Pharma (BBIO) Stock Rally Leans On Attruby As Losses Recede
BridgeBio Pharma's stock saw a modest pullback despite strong Q2 2026 results driven by significant revenue from its flagship drug Attruby, which accounted for the majority of its $243.7 million quarterly revenue. While losses narrowed and pipeline milestones were achieved, concerns remain about the company's heavy reliance on Attruby and potential future dilution from recent financing. Investors are evaluating whether these results signal a turning point or underlying fragility.
BridgeBio’s 56 New Employees Get Awards With Vesting Starting in 2027
BridgeBio Pharma announced equity inducement grants of 66,705 restricted stock units to 56 new employees, with the first quarter vesting on August 16, 2027. These grants are part of an employment inducement plan under Nasdaq Listing Rule 5635(c)(4). The company aims to develop transformative medicines for genetic conditions and uses such awards to attract and retain talent.
BridgeBio Pharma, Inc. Stock 12‑Month Price Target Raised to $109.44, Implies 29% Upside
BridgeBio Pharma, Inc.'s stock (BBIO) has seen its average 12-month price target raised from $107.65 to $109.18 by 19 analysts, implying a potential 29% upside from its Aug. 10 closing price. The consensus rating for BBIO remains a "Buy" among 23 analysts, with 21 recommending a Buy and 2 recommending a Hold.
BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months (NASDAQ:BBIO)
BridgeBio Pharma reported strong Q2 results, exceeding analyst expectations and reaffirming its guidance for Attruby/Beyonttra global sales to surpass $1 billion this year. The company saw a significant surge in Attruby's U.S. net sales and increased Beyonttra royalties, indicating growing market share. BridgeBio's recent $1 billion preferred equity raise is expected to bolster its balance sheet, accelerate commercial efforts, and support its pipeline, with projections for cash flow positivity within 3-4 quarters.
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
BridgeBio Pharma (BBIO) reported a wider-than-expected Q2 2026 loss of 78 cents per share but saw revenues surge 120% year over year to $243.7 million, beating estimates, primarily driven by strong sales of its drug Attruby. The company is also advancing multiple late-stage pipeline programs, including regulatory filings for oral infigratinib, BBP-418, and encaleret, with potential commercial launches anticipated in the coming years.
BRIDGEBIO PHARMA, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $107 FROM $102
Truist Securities has increased its target price for BridgeBio Pharma, Inc. (BBIO.O) from $102 to $107. The news was reported by Reuters. This adjustment reflects an updated outlook on the company's valuation by the financial institution.
Wells Fargo raises BridgeBio Pharma stock price target on launch outlook
Wells Fargo has increased its price target for BridgeBio Pharma (NASDAQ:BBIO) to $102 from $98, maintaining an Overweight rating due to anticipated near-term launches. Despite an 11% year-to-date gain, the stock is considered slightly overvalued. The firm expects further upside after detailed CARDIO-Transform data is presented at ESC later this month and notes impressive 355% revenue growth over the last twelve months, with a Strong Buy consensus from analysts.
BridgeBio Pharma, Inc. Stock 12‑Month Price Target Raised to $109.18, Implies 29% Upside
Analysts have raised the average 12-month price target for BridgeBio Pharma, Inc. (BBIO) stock from $107.65 to $109.44, implying a 29% potential upside from its August 10 closing price. The consensus rating among 23 analysts remains "Buy," with 21 recommending Buy and 2 recommending Hold. This updated target reflects increased confidence in the company's future performance.
Quantinno Capital Management LP Purchases 21,464 Shares of BridgeBio Pharma, Inc. $BBIO
Quantinno Capital Management LP significantly increased its stake in BridgeBio Pharma, Inc. by 199.2% in the first quarter, adding 21,464 shares to reach a total of 32,240 shares valued at $2.39 million. This move is part of broader institutional investment, with firms like Janus Henderson and T. Rowe Price also increasing their positions, bringing institutional ownership to 99.85%. Despite a reported adjusted loss of $0.78 per share, missing estimates, the company saw a 120.4% year-over-year revenue increase to $243.7 million, and analysts maintain a "Moderate Buy" rating with an average price target of $97.33.
BridgeBio Pharma 2026: Revenue $243.68M, EPS ($0.78) — 10-Q Summary
BridgeBio Pharma reported its 2026 quarterly results, showing a significant increase in revenue to $243.68M from $110.57M in the prior year. Despite the revenue growth, the company recorded a net loss of ($152.22M) and a diluted loss per share of ($0.78), though these figures represent an improvement compared to the previous year. Key business highlights include revenue growth driven by Attruby sales, international approvals for Beyonttra, and progress in their regulatory and pipeline initiatives.
Earnings Flash (BBIO) BridgeBio Pharma, Inc. Reports Q2 Revenue $243.7M, vs. FactSet Est of $220.9M
BridgeBio Pharma, Inc. (BBIO) reported its Q2 revenue of $243.7 million, surpassing the FactSet estimate of $220.9 million. The company's stock, traded on Nasdaq, saw a slight increase of 0.22% on August 10, 2026, with year-to-date growth of 10.69%. BridgeBio Pharma focuses on developing treatments for genetic diseases, with several programs ranging from early science to advanced clinical trials.
BridgeBio Pharma earnings up next amid encaleret milestone
BridgeBio Pharma is set to report its second-quarter earnings, with analysts expecting a loss of 60 cents per share on revenues of $222.2 million, driven by strong Attruby sales. Investors are keenly watching the commercial performance and the regulatory progress of encaleret, its experimental drug for autosomal dominant hypocalcemia type 1, which recently received FDA acceptance for review. Despite near-term losses, Wall Street analysts maintain a bullish outlook on the stock due to the potential blockbuster status of encaleret and other pipeline developments.
BridgeBio Pharma: Q2 Earnings Snapshot
BridgeBio Pharma Inc. reported a Q2 loss of $152.2 million, or 78 cents per share, missing analyst expectations of 64 cents per share. Despite the loss, the rare disease drug developer exceeded revenue forecasts, posting $243.7 million against an expected $222.6 million. The company's shares have shown an 11% increase year-to-date and an 82% climb over the last 12 months.
BridgeBio Pharma earnings up next amid encaleret milestone
BridgeBio Pharma is set to release its second-quarter earnings, with analysts expecting a loss of 60 cents per share on revenue of $222.2 million, driven by growing sales of its rare heart condition treatment, Attruby. Investors will focus on commercial execution, gross margins, and the regulatory timeline for encaleret, an experimental drug for autosomal dominant hypocalcemia type 1, which has a PDUFA date of May 8, 2027. Despite near-term losses, Wall Street maintains a bullish outlook, with a mean price target suggesting a 26% upside.
Has BridgeBio Pharma (BBIO) Run Too Far Ahead Of Its Valuation Narrative?
BridgeBio Pharma (BBIO) has seen significant share price gains, with a 30.61% return over 90 days and an 81.37% return over one year, closing at $84.48. While one valuation narrative suggests the stock is 237.9% overvalued with a fair value of $25, Simply Wall St's DCF model indicates it is heavily undervalued with a fair value of $302.55. The discrepancy highlights differing assumptions about the company's future cash generation and the success of its Acoramidis launch.
How Bridgebio Pharma Inc. (BBIO) Affects Rotational Strategy Timing
This article analyzes Bridgebio Pharma Inc. (BBIO) through quantitative research, highlighting a strong near-term sentiment with a long-term positive bias. It presents an exceptional risk-reward setup targeting a 13.9% gain, along with three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles. The analysis also provides multi-timeframe signal insights, including support and resistance levels.
How Bridgebio Pharma Inc. (BBIO) Affects Rotational Strategy Timing
This article analyzes Bridgebio Pharma Inc. (BBIO) using AI models to determine its effect on rotational strategy timing. It highlights a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias, with an exceptional 48.3:1 risk-reward setup. The report provides specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
BridgeBio Pharma, Inc. expected to post a loss of 58 cents a share - Earnings Preview
BridgeBio Pharma, Inc. is projected to report a loss of 58 cents per share in its upcoming earnings. This information is provided as an earnings preview by Reuters, distributed through TradingView News. The article suggests that readers can access more details on TradingView.
Will FDA Review of Encaleret and New Shelf Capacity Change BridgeBio Pharma's (BBIO) Narrative?
BridgeBio Pharma (BBIO) recently received FDA acceptance for its New Drug Application for encaleret, a potential first-in-class therapy for autosomal dominant hypocalcemia type 1, and filed two shelf registrations for US$2.21 billion in common stock. These developments could significantly alter BridgeBio's investment narrative by providing a new revenue stream and financial flexibility, potentially mitigating risks associated with high R&D spend and net losses. Despite the positive catalyst, investors should remain aware of ongoing high costs and the possibility of future equity raises.
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $111
Piper Sandler has reiterated its Buy rating on BridgeBio Pharma (BBIO.US) and maintained a target price of $111. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
BridgeBio Pharma (BBIO) Stock Looks Priced At A Premium Despite 148% Returns
BridgeBio Pharma (BBIO) stock has seen a significant 148% return over the last three years but appears to be priced at a premium, with a current Price/Sales (P/S) ratio of 27.0x, significantly higher than the biotech industry average. Despite FDA acceptance for its key drug candidate, encaleret, the valuation checks suggest the stock leans expensive. Investors are weighing whether the current price reflects too much optimism, given potential execution risks and the gap between its current P/S and a fair P/S of 21.6x.
BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 2,000 Shares
Maricel Apuli, CAO of BridgeBio Pharma (NASDAQ:BBIO), sold 2,000 shares for $160,120 under a pre-arranged trading plan, retaining 127,401 shares. The company's shares traded down 0.2% to $79.96, despite strong revenue growth of 66.8% year-over-year, as it missed EPS expectations. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $95.21.
BridgeBio Pharma (BBIO) Wins FDA Review For Encaleret In ADH1
The FDA has accepted BridgeBio Pharma's New Drug Application (NDA) for encaleret, a potential first-in-class treatment for autosomal dominant hypocalcemia type 1 (ADH1). This acceptance initiates a formal review process with a set target action date. The stock has seen significant returns over the past year and three years, reflecting investor reaction to prior pipeline milestones.
BridgeBio Pharma (NASDAQ: BBIO) CAO sells 2,000 shares in 10b5-1 trading plan
Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma (NASDAQ: BBIO), sold 2,000 shares of common stock on July 30, 2026, at a price of $80.06 per share. This transaction was conducted under a Rule 10b5-1 sales plan adopted on September 8, 2025. Following the sale, Apuli directly holds 127,401 shares of the company's common stock.
